United States
Print page content Print
Increase text size Decrease text size
Text Size

DORMOSEDAN®

(detomidine hydrochloride)

Predictable and effective sedation and analgesia you can count on every time

DORMOSEDAN is an a2 adrenoceptor agonist that provides non-narcotic sedation and analgesia that can be used safely in horses for a variety of minor surgical and diagnostic procedures. The greater a2 selectivity of DORMOSEDAN allows it to bind specifically to a2 adrenoceptors to produce predictable and effective sedation and analgesia.

Expand All
  • Predictable Sedation

    • a2 selectivity makes DORMOSEDAN predictable and effective
    • Only  a2 -agonist which has significant analgesia extending more than 15 minutes post administration1, 2, 3
    • DORMOSEDAN provides non-narcotic sedation with a wide margin of safety

  • Greater a2 selectivity and dosing flexibility

    • DORMOSEDAN allows dosing flexibility so you can accurately regulate the depth and length of sedation and analgesia
    • Simple dosing: 1 or 2 mL per 1,100 lbs horse IM or IV
    • Whether administered IV or IM, DORMOSEDAN produces rapid onset of effect (5 minutes for IV,10 to15 minutes for IM)
    • Xylazine can bind with a1 and non-a2 receptor sites, producing variable neurological effects4
    • DORMOSEDAN’s potency is 80 to 100 times greater than xylazine in sedation and analgesic effect5
    • Effects may be maintained up to 2 hours depending on dose level and route of administration, with analgesia being more pronounced following IV injection
    • Additional dosing prolongs not depends sedation
    • Zoetis does not recommend the use at higher than the approved label dosed
    Packaging
    • 5- and 20-mL multidose vials

    1. Moens Y, Lanz F, Doherr MG, Schatzmann U. A comparison of the
      antinociceptive effects of xylazine, detomidine and romifidine on experimental pain in horses. Vet Anesth Analg 2003;30(3);183-190.
    2. Kamerling SG, Winter MT, et. al. Objective assessment of detomidine-induced analgesia and sedation in the horse. Eur J Pharmacol 1988;151;1-8.
    3. Jochle W, Baker GJ, et. al. Comparison of detomidine, butorphanol, flunixin meglumine and xylazine in clinical cases of equine colic. Eq Vet J 1989;7;111-116.
    4. Virtanen R, Savola V, et.al. Characterization of the selectivity, specificity and potency of medetomidine as an a2  adrenocepter agonist. Eur J Pharmacol 1988;150:9–14.
    5. Daunt D. Detomidine in equine sedation and analgesia. Comp Cont Edu 1995;17:1405–1411.

     


IMPORTANT SAFETY INFORMATION
Do not use DORMOSEDAN Sterile Solution in horses with pre-existing atrioventricular (AV) or sinoatrial (SA) block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Do not use in anesthetized or sedated horses, or in conditions of shock, severe debilitation or stress due to extreme heat, cold, fatigue or high altitude. Do not use in horses intended for human consumption. Handle dosing syringes with caution to avoid direct exposure to skin, eyes or mouth. See full Prescribing Information.